INTRODUCTION
============

Nonalcoholic fatty liver disease (NAFLD) has been recognized as the leading cause of chronic liver disease, with a prevalence up to 20%--30% in the general population.[@b1-gnl-12-316] Most cases of NAFLD follow a benign clinical course, however, once simple steatosis progresses to nonalcoholic steatohepatitis (NASH), 25% of patients may experience further progression to liver fibrosis and cirrhosis.[@b2-gnl-12-316],[@b3-gnl-12-316] Furthermore, patients with NASH have increased liver-related mortality compared with the general population.[@b4-gnl-12-316] Genetic and environmental factors have important roles in the development of NAFLD.[@b5-gnl-12-316],[@b6-gnl-12-316] Single-nucleotide polymorphisms (SNPs) are widely used to identify genetic factors in various common diseases.

The first genome-wide association study (GWAS) of NAFLD found that a SNP (rs738409, encoding I148M) in the patatin-like phospholipase domain-containing protein 3 (*PNPLA3*) gene on chromosome 22 conferred susceptibility to NAFLD in a population that included Hispanic, African-American and European-American individuals. Subjects homozygous for this allele showed a 2-fold increase in hepatic fat content compared to noncarriers.[@b7-gnl-12-316] A systematic review showed that rs738409 GG genotype was associated not only with liver fat accumulation but also with susceptibility to more aggressive disease.[@b8-gnl-12-316] A recent GWAS of a European population identified four additional variants associated with NAFLD including neurocan (NCAN), glucokinase regulatory protein (GCKR), lysophospholipase-like 1 (LYPLAL1) and protein phosphatase 1 regulatory subunit 3b (PPP1R1B).

Although genetic features and their contributions differ among ethnicities, there are few studies incorporating GWAS of Asian populations. In a Japanese study, there was a significant association of the *PNPLA3* gene with histologically diagnosed NAFLD.[@b9-gnl-12-316] Another GWAS in Japan reported the association of two additional genes with the development and progression of NAFLD.[@b10-gnl-12-316] The aim of this study was to evaluate the associations of genome-wide SNPs with the presence and severity of NAFLD in a Korean population.

MATERIALS AND METHODS
=====================

1. Study population
-------------------

For our study, we analyzed the database from a previously described GENIE cohort.[@b11-gnl-12-316] Briefly, 8,000 people donated blood samples during a routine health check-up program at Seoul National University Hospital Healthcare System Gangnam Center between January 2014 and December 2014, and their blood samples were stored at a biorepository with their informed consent.

Subjects with significant alcohol intake (\>20 g/day for males and \>10 g/day for females) were excluded (n=842). We also excluded 248 individuals who were positive for hepatitis B virus and 48 subjects who were positive for hepatitis C virus. Additionally, subjects with missing information were excluded from the study. This study was approved by the Institutional Review Board (No. 1601-010-730) of the Seoul National University Hospital with a waiver of informed consent.

2. Clinical and laboratory assessments
--------------------------------------

Each subject completed a past medical history questionnaire and underwent anthropometric assessment. The laboratory and radiological tests were performed on the same day. The body weight and height of each subject were measured using a digital scale. Body mass index (BMI) was calculated as the ratio of weight (kg) to area (m^2^, estimated from height). Waist circumference was measured at the midpoint between the lower costal margin and the anterior superior iliac crest by a well-trained person. Systolic blood pressure and diastolic blood pressure were each measured twice, and their mean values were reported. After an overnight 12 hours period, blood samples were collected from the antecubital vein of each individual. The laboratory evaluations included serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), total cholesterol, triglyceride, high density lipoprotein cholesterol, fasting glucose, hepatitis B surface antigen and antibody to hepatitis C virus. Abnormal liver enzyme levels were defined as elevated serum ALT above the strict cutoff point based on the updated definition (ALT \>30 IU/ L for male and \>19 IU/L for female) by Prati *et al*.[@b12-gnl-12-316] We defined the suspected NASH as presence of ultrasonographic fatty liver with serum ALT elevation. Hypertension was defined as having systolic blood pressure ≥140 mm Hg, having diastolic blood pressure ≥90 mm Hg or using of anti-hypertensive medication. Diabetes mellitus was defined as either a fasting serum glucose level of ≥126 mg/dL or the use of anti-diabetic medication.

The diagnosis of NAFLD was based on the ultrasonographic findings (Aloka a-10, Aloka, Tokyo, Japan) of experienced radiologists who were unaware of the clinical information. The sonographic features of fatty liver were classified based on previously described standard categories as follows;[@b13-gnl-12-316],[@b14-gnl-12-316] normal, normal echogenicity; mild, slight diffuse increase in bright homogenous echoes in the liver parenchyma, with normal visualization of the diaphragm and the portal and hepatic vein borders, and with normal hepatorenal contrast if echogenic; moderate, diffuse increase in bright echoes in the liver parenchyma, with slightly impaired visualization of the peripheral portal and hepatic vein borders; severe, marked increase in bright echoes at a shallow depth, with deep attenuation and impaired visualization of the diaphragm and marked vascular blurring.

3. Genome-wide genotyping and quality control
---------------------------------------------

Genomic DNA was isolated from venous blood samples and 200 ng of DNA from each patient was genotyped using Axiom^®^ Customized Biobank Genotyping Arrays (Affymetrix, Santa Clara, CA, USA). The PLINK program version 1.07 (Free Software Foundation Inc., Boston, MA, USA) was used for quality control procedures. Samples meeting any of the following criteria were removed: (1) gender inconsistency, (2) call rate ≤97%, and (3) related and cryptically related individuals (identical by descent \>0.185). SNPs were filtered if (1) the call rate was \<95%, (2) the minor allele frequency was ≤0.01 (n=172,546), or (3) there was a significant deviation from the Hardy-Weinberg equilibrium permutation test (p\<0.0001). After quality control, 584,061 autosomal SNPs remained for the association analysis.

4. Statistical analysis
-----------------------

A total of 584,061 SNPs that passed the quality control were used for the GWAS. We used the multivariable logistic regression model in the PLINK software package (version 1.07) and ordinal logistic regression in the R statistical software package version 3.1.1 (R development Core Team; R Foundation for Statistical Computing, Vienna, Austria) to test the association of NAFLD with SNPs in the genome. Age, gender and BMI were used as covariates. The R statistical software package, was used for the statistical analysis and to draw the Manhattan plot of −log10.

The results were verified using discovery and validation sets. We divided the enrolled population into two groups based on the time of enrollment. Samples from subjects who enrolled from January 2014 to October 2014 were used as the discovery set, and samples from subjects who enrolled in the subsequent months were used as the validation set. Comparisons of continuous variables between the two groups were performed using Student t-test, and categorical variables were compared using a chi-square test or Fisher exact test. Logistic regression analysis was used to analyze the association between NAFLD and control groups while controlling for potential confounders. Ordinal logistic regression analysis was used to analyze the association according to the severity of NAFLD. SNPs that had a p-value of less than 8.56×10^−8^ (calculated by the Bonferroni correction method) in the discovery set were re-evaluated in the validation set. p-values of less than 0.05 in the validation set were considered significant.

RESULTS
=======

1. Study populations
--------------------

A total of 6,290 subjects were included. The mean subject age was 50.0±10.6 years, and 53.9% of the subjects were male. Based on the definition described in the methods, there were 4,409 samples in the discovery set and 1,881 samples in the validation set. The characteristics of the study population are described in [Table 1](#t1-gnl-12-316){ref-type="table"}. The subjects in the validation set showed greater proportions of male, NAFLD and suspected NASH, and higher diastolic pressure, ALT, BMI and fasting glucose (p\<0.05).

2. Genome-wide association analysis of NAFLD
--------------------------------------------

We first evaluated genome-wide associations in the discovery set, with a significance threshold of p\<8.56×10^−8^ as the threshold after adjusting for age, gender and BMI. [Fig. 1](#f1-gnl-12-316){ref-type="fig"} shows a Manhattan plot with one peak, located on chromosome 22, that was associated with NAFLD. In the discovery set of the GWAS, seven SNPs on two chromosomes were significantly associated with NAFLD and we performed a validation test with the validation set, all remained significant ([Table 2](#t2-gnl-12-316){ref-type="table"}). Among them, three SNPs, namely, rs738409, rs12483959, and rs2281135 located in the *PNPLA3* gene showed strong associations with NAFLD (discovery set: p=1.74×10^−15^, p=5.79×10^−15^, and p=9.72×10^−15^; validation set: p=2.56×10^−8^, p=1.34×10^−8^, and p=1.29×10^−7^, respectively). All the three SNPs were in strong linkage disequilibrium (LD; r^2^\>0.9). An additional three SNPs, including rs3761472, rs2143571, and rs2073080 located in the *SAMM50* gene, were in strong LD (r^2^\>0.9) showed significant associations with NAFLD (discovery set: p=2.22×10^−11^, p=1.88×10^−11^, and p=2.72×10^−11^; validation set: p=3.28×10^−7^, p=5.86×10^−7^, and p=7.83×10^−7^, respectively). In addition, rs58542926, located in the *TM6SF*2 gene showed a weak association with NAFLD (discovery set, p=6.08×10^−8^; validation set, p=0.01385).

3. Impact of SNPs on the severity of NAFLD
------------------------------------------

We next investigated the associations of the SNPs found in the GWAS with NAFLD severity based on ultrasonographic grade, namely, normal versus mild versus moderate versus severe. The ordinal logistic regression analysis after adjusting for age, gender and BMI showed that that 10 SNPs showed significant associations with the severity of NAFLD ([Table 3](#t3-gnl-12-316){ref-type="table"}). Among them, three SNPs (rs738409, rs12483959, and rs2281135, located in the *PNPLA3* gene) that had shown strong associations with the presence of NAFLD, also showed strong associations with the severity of NAFLD (discovery set: p=2.02×10^−19^, p=1.42×10^−18^, and p=2.21×10^−18^; validation set: p=1.70×10^−8^, p=5.14×10^−9^, and p=4.92×10^−8^, respectively). An additional three SNPs (rs3761472, rs2143571, and rs2073080 located in the *SAMM50* gene), showed significant associations with the severity of NAFLD (discovery set: p=1.03×10^−14^, p=1.08 ×10^−14^, and p=1.97×10^−14^; validation set: p=2.07×10^−7^, p=9.01×10^−7^, and p=1.03×10^−6^, respectively).

Finally we further stratified the subjects with NAFLD by serum ALT levels, as a possible proxy for NASH comparing; normal versus NAFLD with normal ALT versus NAFLD with elevated ALT (\>30 for male and 19 for female, IU/L), which may reflect the presence of suspected NASH, and examined the association between SNPs and suspected NASH. We found that eight SNPs that had significant relationships with the severity of NAFLD also showed significant associations fatty liver with elevated ALT. Among them, rs58542926, located in the *TM6SF* gene, showed significant associations with suspected NASH (discovery set, p=2.85×10^−8^; validation set, p=0.0018) ([Table 4](#t4-gnl-12-316){ref-type="table"}).

When diabetes was added as an adjustment factor in both analysis, there was no change in the significant SNPs (data were not shown).

4. Analysis of metabolic traits and NAFLD-suspected SNPs
--------------------------------------------------------

Because NAFLD is recognized as a hepatic manifestation of metabolic syndrome, we investigated the associations between metabolic traits and NAFLD-suspected SNPs. Six SNPs were associated with increased serum ALT and AST levels in the NAFLD group, but not in the control group (p-values \<0.0001) ([Table 5](#t5-gnl-12-316){ref-type="table"}). Other metabolic traits were not significantly associated with the six SNPs.

DISCUSSION
==========

The significant associations between the *PNPLA3* gene and NAFLD are well-known. However, there has been no study based on GWAS in a Korean population. In this study, we investigated the significance of association between the *PNPLA3* gene and ultrasonography-diagnosed NAFLD or NAFLD severity. Moreover, we demonstrated that *SAMM50* and *TM6SF*2 are most likely involved in NAFLD in the Korean population.

Romeo *et al*.,[@b7-gnl-12-316] previously found that rs738409 is associated with increased hepatic fat, as measured by magnetic resonance spectroscopy in Hispanic, African American and European populations. Other groups have replicated significant associations between the SNP and fatty liver.[@b8-gnl-12-316],[@b15-gnl-12-316],[@b16-gnl-12-316] In addition, many subsequent studies were performed to identify new SNPs with roles in the development and progression of NAFLD.[@b17-gnl-12-316],[@b18-gnl-12-316] However, previous studies has been primarily based on European or American populations. Because there are genetic variations among different ethnicities, it is valuable to evaluate the genetic background of NAFLD in Asian populations. In a GWAS using a Japanese population, SNPs in the *PNPLA3* and *SAMM50* genes were significantly associated with NAFLD, in accord with our results.[@b9-gnl-12-316],[@b10-gnl-12-316],[@b19-gnl-12-316] We observed that the SNPs that were associated with the presence of NAFLD also showed significant associations with the severity of NAFLD.

Although ultrasonography is widely used as a first-line method to detect NAFLD according to practical clinical guidelines,[@b20-gnl-12-316],[@b21-gnl-12-316] ultrasonography has limitations when grading the severity of NAFLD.[@b22-gnl-12-316] A recent prospective study reported that serum ALT level elevation was associated with the degree of hepatic steatosis.[@b23-gnl-12-316] Thus, in our study, we further stratified NAFLD subjects according to their ALT levels. Using criteria for NAFLD categorization that were similar those in our study, Sung *et al*.[@b24-gnl-12-316] showed that overall cardiovascular risk was significantly greater in NASH, defined as steatosis accompanied by increased serum ALT levels, than in either simple steatosis or elevated ALT alone, suggesting that the NAFLD categories used in this study are useful for predicting the prognosis of NAFLD. We found significant associations of the *PNPLA3* gene with suspected NASH in our study, consistent with previous studies showing association of rs738409 with serum ALT levels in Japanese[@b18-gnl-12-316] and U.S. populations.[@b25-gnl-12-316]

The *PNPLA3* gene is involved in lipid metabolism and modulates hepatic triglyceride accumulation. Recently, rs738409 was associated with decreased serum levels of triglycerides in type 2 diabetes.[@b10-gnl-12-316],[@b26-gnl-12-316] In addition, homozygous carriers of the *PNPLA3* risk allele showed higher levels of fasting glucose than heterozygous carriers.[@b27-gnl-12-316] However, inconsistencies remain, there are no significant associations between rs738409 and NAFLD-related metabolic traits[@b28-gnl-12-316] in consistent with our results. These findings suggest the possibility of disconnect between metabolic risk factors and the risk of NAFLD conferred by rs738409. Metabolic syndrome may be related to obesity, dyslipidemia, hypertension and glucose intolerance while NAFLD may be more related to endogenous genetic predispositions toward fat accumulation in the liver. The role of *SAMM50* and *TM6SF*2 in lipid metabolism and hepatic triglycerides accumulation have been reported. However, controversies remain that *SAMM50* gene were associated with reduced or increased levels of serum triglycerides.[@b10-gnl-12-316],[@b29-gnl-12-316] *TM6SF*2 was known to be a regulator of hepatic fat metabolism.[@b30-gnl-12-316],[@b31-gnl-12-316] Further studies are needed to confirm the mechanism by which metabolic traits and NAFLD are associated.

The strength of our study is that this is the first genetic analysis based on GWAS regarding NAFLD in Korean population, reflecting ethnic characteristics. Moreover, because of the relatively large sample size, the results of our study might have adequate statistical power.

There are several limitations in this study. First, we selected the discovery set and the validation set from the same population (those who had regular health check-ups at our institute). In the future, a validation study should be performed using a different population set. Second, because the study population was based on subjects who visited a single health screening center in Korea for health check-ups, it may not be representative of the general population, and there might be a selection bias. Third, it is impossible to discriminate normal, NAFLD and NASH using single ultrasonographic exam and serum ALT level. Fourth, hepatic sonography cannot diagnose a small fatty infiltration below 30% and it is not so much accurate as Fibroscan or liver biopsy to measure the degree of fatty liver, thus there may be the possible measurement bias. Finally, we cannot identify the effect of insulin resistance as a metabolic trait because there was no data regarding insulin levels in this study.

In conclusion, we demonstrated that the *PNPLA3* and *SAMM50* genes are significantly associated with the presence and severity of NAFLD in a Korean population. These findings confirm the important roles of genetic factors in the pathogenesis of NAFLD.
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###### 

Baseline Characteristics of the Study Population

  Characteristic                    Discovery set (n=4,409)   Validation set (n=1,881)   p-value
  --------------------------------- ------------------------- -------------------------- ---------
  Age, yr                           50.2±10.5                 50.0±9.9                   0.509
  Male sex                          2,321 (52.6)              1,067 (56.7)               0.003
  Diabetes mellitus                 286 (6.5)                 111 (5.9)                  0.382
  Hypertension                      491 (11.1)                237 (12.6)                 0.106
  Systolic blood pressure, mm Hg    114.6±13.4                115.3±13.1                 0.077
  Diastolic blood pressure, mm Hg   74.9±10.3                 76.1±10.0                  \<0.001
  Body mass index, kg/m^2^          22.9±3.0                  23.2±3.0                   0.002
  Waist circumference, cm           82.0±8.8                  82.0±8.7                   0.850
  AST, IU/L                         22.5±9.4                  22.9±10.2                  0.189
  ALT, IU/L                         22.2±15.1                 23.4±16.7                  0.009
  Cholesterol, mg/dL                192.7±33.7                194.5±34.2                 0.046
  Triglycerides, mg/dL              104.2±69.8                107.0±72.1                 0.142
  HDL cholesterol, mg/dL            53.9±11.9                 53.7±11.9                  0.644
  LDL cholesterol, mg/dL            121.1±30.2                122.4±30.4                 0.128
  Fasting glucose, mg/dL            97.1±15.3                 98.8±18.6                  \<0.001
  NAFLD                             1,593 (36.1)              744 (39.6)                 0.011
   Severity of NAFLD                                                                     0.049
    No fatty liver                  2,816 (63.9)              1,137 (60.5)               
    Mild                            981 (22.2)                456 (24.2)                 
    Moderate                        547 (12.4)                251 (13.3)                 
    Severe                          65 (1.5)                  37 (2.0)                   
   Suspected NASH                                                                        0.026
    No fatty liver                  2,797 (63.9)              1,131 (60.5)               
    Fatty liver with normal ALT     925 (21.1)                420 (22.4)                 
    Fatty liver with elevated ALT   656 (15.0)                320 (17.1)                 

Data are presented as the mean±SD or number (%).

AST, aspartate aminotransferase; ALT, alanine aminotransferase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis.

###### 

SNPs Associated with NAFLD in a Korean Population

  SNP          Chromosome   Position   Nearest genes   Risk allele   Discovery   Validation                                                                             
  ------------ ------------ ---------- --------------- ------------- ----------- ------------ ---------------------- ---------- ------- -------- ---------------------- ----------
  rs58542926   19           19379549   TM6SF2          T             0.094       0.066        1.671 (1.387--2.012)   6.08E-8    0.086   0.070    1.419 (1.074--1.875)   0.01385
  rs738409     22           44324727   PNPLA3          G             0.466       0.398        1.537 (1.383--1.709)   1.74E-15   0.467   0.382    1.542 (1.324--1.797)   2.56E-08
  rs12483959   22           44325996   PNPLA3          A             0.465       0.397        1.525 (1.365--1.686)   5.79E-15   0.467   0.3382   1.556 (1.336--1.812)   1.34E-08
  rs2281135    22           44332570   PNPLA3          A             0.464       0.396        1.517 (1.365--1.686)   9.72E-15   0.459   0.379    1.509 (1.295--1.757)   1.29E-07
  rs3761472    22           44368122   SAMM50          G             0.450       0.390        1.431 (1.288--1.590)   2.22E-11   0.451   0.378    1.489 (1.278--1.735)   3.28E-07
  rs2143571    22           44391686   SAMM50          A             0.453       0.395        1.437 (1.292--1.597)   1.88E-11   0.448   0.380    1.475 (1.266--1.717)   5.86E-07
  rs2073080    22           44394402   SAMM50          T             0.454       0.395        1.432 (1.288--1.591)   2.72E-11   0.449   0.380    1.467 (1.260--1.708)   7.83E-07

An additive genetic model was used.

SNPs, single-nucleotide polymorphisms; NAFLD, nonalcoholic fatty liver disease; OR, odds ratio; CI, confidence interval.

p-values are adjusted for age, sex and body mass index.

###### 

SNPs Associated with the Severity of NAFLD in a Korean Population

  SNP          Chromosome   Position   Nearest genes   Risk allele   Discovery   Validation                                                                
  ------------ ------------ ---------- --------------- ------------- ----------- ------------ ---------------- ---------- ------- ------- ---------------- ----------
  rs58542926   19           19379549   TM6SF2          T             0.094       0.066        0.489 (0.086)    1.15E-08   0.086   0.069   0.335 (0.128)    0.008
  rs2965185    19           19525792   GATAD2A         C             0.177       0.142        0.347 (0.064)    7.54E-08   0.181   0.151   0.248 (0.095)    0.009
  rs139051     22           44324676   PNPLA3          G             0.342       0.382        −0.302 (0.060)   1.83E-09   0.343   0.394   −0.269 (0.074)   0.0002
  rs738409     22           44324727   PNPLA3          G             0.466       0.398        0.444 (0.049)    2.02E-19   0.467   0.382   0.399 (0.071)    1.70E-08
  rs12483959   22           44325996   PNPLA3          A             0.465       0.397        0.433 (0.049)    1.42E-18   0.467   0.382   0.414 (0.071)    5.14E-09
  rs2281135    22           44332570   PNPLA3          A             0.464       0.396        0.429 (0.049)    2.21E-18   0.459   0.379   0.386 (0.071)    4.92E-08
  5s3761472    22           44368122   SAMM50          G             0.45        0.390        0.378 (0.049)    1.03E-14   0.451   0.378   0.369 (0.071)    2.07E-07
  rs2143571    22           44391686   SAMM50          A             0.453       0.395        0.380 (0.049)    1.08E-14   0.448   0.380   0.348 (0.071)    9.01E-07
  rs2073080    22           44394402   SAMM50          T             0.454       0.395        0.376 (0.049)    1.97E-14   0.449   0.380   0.345 (0.071)    1.03E-06
  rs1007863    22           44395451   PARVB           T             0.466       0.500        −0.277 (0.049)   1.69E-08   0.458   0.491   −0.290 (0.070)   3.17E-05

Genomic position is based on NCBI build 37.

SNPs, single-nucleotide polymorphisms; NAFLD, nonalcoholic fatty liver disease; SE, standard error.

p-values are adjusted for age, sex and body mass index.

###### 

SNPs Associated with NAFLD and Elevated ALT

  SNP          Chromosome   Position   Nearest genes   Risk allele   Discovery   Validation                                                                
  ------------ ------------ ---------- --------------- ------------- ----------- ------------ ---------------- ---------- ------- ------- ---------------- ----------
  rs58542926   19           19379549   TM6SF2          T             0.066       0.093        0.480 (0.086)    2.85E-08   0.086   0.070   0.400 (0.128)    0.00180
  rs139051     22           44324676   PNPLA3          G             0.382       0.342        −0.280 (0.050)   2.44E-08   0.341   0.392   −0.233 (0.074)   0.00170
  rs738409     22           44324727   PNPLA3          G             0.397       0.466        0.410 (0.049)    8.44E-17   0.468   0.384   0.375 (0.071)    1.42E-07
  rs12483959   22           44325996   PNPLA3          A             0.397       0.464        0.403 (0.049)    3.29E-16   0.468   0.383   0.383 (0.071)    8.89E-08
  rs2281135    22           44332570   PNPLA3          A             0.395       0.463        0.398 (0.049)    5.91E-16   0.460   0.381   0.346 (0.071)    1.08E-06
  rs3761472    22           44368122   SAMM50          G             0.390       0.450        0.349 (0.049)    9.66E-13   0.452   0.379   0.348 (0.072)    1.14E-06
  rs2143571    22           44391686   SAMM50          A             0.396       0.453        0.347 (0.049)    1.65E-12   0.450   0.380   0.339 (0.072)    1.72E-06
  rs2073080    22           44394402   SAMM50          T             0.395       0.453        0.344 (0.049)    2.31E-12   0.451   0.381   0.341 (0.071)    1.46E-06

An additive genetic model was used.

SNPs, single-nucleotide polymorphisms; NAFLD, nonalcoholic fatty liver disease; ALT, alanine aminotransferase; SE, standard error.

p-values are adjusted for age, sex and body mass index.

###### 

Associations between Significant SNPs and Metabolic Factors

  SNP          Subjects   Fasting glucose   Triglycerides   HDL              Cholesterol                                               
  ------------ ---------- ----------------- --------------- ---------------- ------------- ---------------- --------- ---------------- ---------
  rs58542926   Control    −0.081 (0.006)    0.002           −0.070 (0.024)   0.003         0.560 (0.600)    0.350     1.742 (1.745)    0.318
               NAFLD      0.042 (0.009)     0.636           −0.104 (0.03)    5.5×E-4       1.357 (0.582)    0.012     −2.002 (2.175)   0.357
  rs738409     Control    −0.018 (0.006)    7.4×E-4         −0.003 (0.012)   0.019         0.080 (0.309)    0.797     −0.988 (0.896)   0.270
               NAFLD      −0.001 (0.005)    0.848           −0.054 (0.002)   0.002         0.614 (0.341)    0.072     0.393 (1.276)    0.758
  rs12483959   Control    −0.01 (0.003)     9.6×E-4         −0.027 (0.012)   0.033         0.038 (0.310)    0.903     −1.004 (0.900)   0.265
               NAFLD      −9E04 (0.005)     0.862           −0.054 (0.018)   0.002         0.614 (0.341)    0.072     0.429 (1.276)    0.737
  rs2281135    Control    −0.010 (0.003)    0.001           −0.02 (0.012)    0.088         −0.039 (0.309)   0.900     −0.812 (0.896)   0.365
               NAFLD      0.001 (0.005)     0.791           −0.048 (0.018)   0.006         0.592 (0.340)    0.081     0.414 (1.273)    0.745
  rs3761472    Control    −0.009 (0.003)    0.002           −0.020 (0.012)   0.107         0.017 (0.306)    0.956     −0.351 (0.890)   0.693
               NAFLD      0.005 (0.005)     0.321           −0.031 (0.018)   0.080         0.864 (0.342)    0.011     2.116 (1.278)    0.098
  rs2143571    Control    0.001 (0.003)     6.3×E-4         −0.012 (0.012)   0.108         0.007 (0.306)    0.956     −0.819 (0.894)   0.360
               NAFLD      0.004 (0.005)     0.493           −0.003 (0.018)   0.137         0.878 (0.341)    0.010     2.560 (1.278)    0.045
  rs2073080    Control    −0.001 (0.003)    6.6×E-4         −0.019 (0.012)   0.121         −0.017 (0.309)   0.956     −0.871 (0.896)   0.331
               NAFLD      0.004 (0.005)     0.466           −0.027 (0.018)   0.121         0.934 (0.341)    0.006     2.467 (1.275)    0.038
                                                                                                                                       
                          SBP               DBP             ALT              AST                                                       
                                                                                                                                       
  rs58542926   Control    −0.352 (0.496)    0.478           −0.575 (0.656)   0.380         0.006 (0.022)    0.790     0.002 (0.015)    0.868
               NAFLD      0.265 (0.559)     0.636           0.522 (0.572)    0.488         0.102 (0.030)    5.7×E-4   0.523 (0.019)    0.007
  rs738409     Control    −0.316 (0.255)    0.215           −0.509 (0.337)   0.131         −0.018 (0.011)   0.113     −0.003 (0.008)   0.673
               NAFLD      −0.181 (0.331)    0.585           −0.106 (0.445)   0.811         0.084 (0.017)    6.0×E-7   0.051 (0.011)    7.6×E-6
  rs12483959   Control    −0.308 (0.255)    0.228           −0.581 (0.338)   0.086         −0.021 (0.012)   0.069     −0.004 (0.008)   0.644
               NAFLD      −0.227 (0.330)    0.493           −0.257 (0.443)   0.561         0.086 (0.017)    6.0×E-7   0.051 (0.011)    7.6×E-6
  rs2281135    Control    −0.257 (0.255)    0.314           −0.562 (0.337)   0.095         −0.020 (0.011)   0.083     −0.005 (0.008)   0.546
               NAFLD      −0.114 (0.330)    0.729           −0.093 (0.443)   0.835         0.087 (0.017)    6.0×E-7   0.050 (0.011)    9.7×E-6
  rs3761472    Control    0.144 (0.253)     0.560           −0.353 (0.334)   0.292         −0.192 (0.011)   0.901     −0.005 (0.007)   0.493
               NAFLD      0.228 (0.332)     0.492           0.082 (0.445)    0.853         0.084 (0.017)    1.3×E-6   0.049 (0.011)    1.8×E-5
  rs2143571    Control    −0.142 (0.254)    0.577           −0.413 (0.336)   0.220         −0.021 (0.011)   0.062     −0.007 (0.008)   0.367
               NAFLD      0.256 (0.332)     0.441           0.156 (0.446)    0.727         0.081 (0.017)    3.5×E-6   0.049 (0.011)    1.8×E-5
  rs2073080    Control    −0.173 (0.255)    0.497           −0.449 (0.337)   0.183         −0.020 (0.011)   0.075     −0.007 (0.008)   0.383
               NAFLD      0.312 (0.331)     0.346           0.236 (0.444)    0.596         0.080 (0.017)    3.7×E-6   0.049 (0.011)    2.1×E-5

Data were derived from a linear regression analysis. Each metabolic factor was adjusted for age, gender and body mass index. Genomic position is based on NCBI build 37.

SNPs, single-nucleotide polymorphisms; HDL, high-density lipoprotein; SE, standard error; NAFLD, nonalcoholic fatty liver disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; ALT, alanine aminotransferase; AST, aspartate aminotransferase.

[^1]: Goh Eun Chung and Young Lee contributed equally to this work as first authors.
